Sign in
Taking peopleNo phase

Dexamethasone and Pregnancy: Maternal Effects

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France17 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
35 people, planned
Started
30 Sept 2024
Expected to end
30 Dec 2028
Type of study
Observational
Record updated
17 December 2024

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Femme majeure (âge ≥ 18 ans)
  • Grossesse avec indication de traitement anténatal par dexaméthasone (DEX) en accord avec le PNDS :; Mutation sévère du gène CYP21A2 chez chacun des parents; Fœtus féminin
  • Grossesse unique
  • Ayant commencé un traitement anténatal par DEX depuis au moins 24h

Who cannot take part

  • Contraindication to dexamethasone treatment
  • Objection to use of data
  • Persons under legal protection (curatorship, guardianship), court-appointed guardians

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will analyze obstetric, endocrine and metabolic follow-up data in women treated with DEX. It will reveal the prevalence and importance of weight gain, insomnia, edema, stretch marks, arterial hypertension and gestational diabetes, describe pregnancy outcome, and analyze the corticotropic axis during and up to 3 months after pregnancy, with the aim of improving the management of these women and preventing comorbidities.

Read full original descriptionShow less

A few studies suggest problems in women treated with DEX during pregnancy. However, all these studies are retrospective, based on self-questionnaires, and have not evaluated all pregnancy outcomes. Moreover, it would appear that a third of women treated with DEX no longer wish to resume the treatment (8). Compliance with treatment is strongly linked to its efficacy. It is therefore important to start investigating the pregnancy outcomes of women treated with DEX. This project is relevant because it has the potential to improve current clinical practice and recommendations related to this treatment, and thus have a direct impact on future patient care. The results of this study will guide us in the management of women presenting an indication for prenatal DEX treatment, and will help to inform the Order of November 15, 2022.

The group in the trial

  • women treated with dexamethasone during pregnancy at risk of Congenital Adrenal Hyperplasia

    All women treated with DEX during pregnancy at risk of Congenital Adrenal Hyperplasia over the defined period (retrospective and prospective).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Obstetrical, Endocrine and Metabolic Consequences of Antenatal Dexamethasone Treatment in Pregnant Women at Risk of Congenital Adrenal Hyperplasia
Record updated
17 December 2024